Key positives include a real, diversified revenue base in animal health, strong commitment to R&D with multiple high‑status regulatory approvals, and a reasonably solid balance sheet supported by fresh equity capital and moderate leverage. The company has positive operating cash flow, at least for the reported period, and a broad, evolving product portfolio that spans several livestock species with early steps into overseas and companion animal markets.

Main risks center on the current lack of profitability, very high operating costs relative to revenue, and only modest liquidity cushion. The business still relies on external funding to support its growth and R&D agenda, which could become more challenging if market conditions or investor sentiment weaken. Competitive pressures from larger domestic and multinational peers, volatility in livestock markets, and the inherent uncertainty of R&D and regulatory outcomes add further layers of risk.

Looking ahead, ZYBT appears to be in an investment and build‑out phase: it is trading near‑term profitability for innovation, portfolio expansion, and market positioning. The longer‑term trajectory will hinge on whether its new vaccines and geographic and segment expansions (especially in companion animals) can scale enough to absorb the heavy cost structure and turn the business sustainably profitable. Until there is clearer evidence of improving margins and consistent cash generation, financial performance is likely to remain volatile and sensitive to execution in both R&D and commercialization.